Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

ApTOLL ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)

Coordinator
Aptatargets SL, Spain
Runs
1 January 2024 to 31 March 2026
Status
Running
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101163492

What the project is doing

In the project's own words, from its summary on CORDIS.

Stroke is a devastating medical condition affecting 15 million people worldwide yearly, being Ischemic Stroke the most frequent (87%). Indeed, the global cost of stroke is >847b (60b in EU) due to the huge socioeconomic burden of disabilities. Reperfusion treatment improves outcomes, but only 20% of patients are currently eligible for treatment due to the narrow therapeutic window after stroke symptom onset and stringent selection criteria for eligibility.

Novel therapies - small molecules or biologics - targeting neuroprotection have not achieved enough efficacy to get approved. aptaTargets has successfully developed ApTOLL, an immune modulator and neuroprotectant with a novel approach TO REDUCE BRAIN DAMAGE in AIS patients. aptaTargets ApTOLL drug has a novel approach targeting TLR4 to reduce brain damage in acute ischemic stroke (AIS) patients (47% reduction of FIV), reduce mortality from 18% to 4% and improve functional outcomes.

Due to the innovative MODE OF ACTION AND NATURE of the molecule (an aptamer), ApTOLL represents a novel and disruptive approach to treating stroke in the first hours after the onset (acute phase), substantially reducing brain damage and improving Quality of Life (QoL) in short and long time. ApTOLL is targeting the Multi-Billion Market of the global Stroke Management Market, valued at 31.7Bn in 2020 and expected to reach 67.7Bn in 2030 (7.8% CAGR).

As a first indication within the scope of this EIC Accelerator proposal, ApTOLL will target AIS patients (87%) who received EVT therapy, expecting to be potentially used as neuroprotectant in all stroke patients, based on preclinical and clinical results. The EIC project aims to conduct the Ph2b trial of ApTOLL and demonstrate its efficacy before entering Ph3. It will boost our chances of licencing the product to a pharma company, increasing the value of the agreement.

Topics

Who is involved

OrganisationCityCountryRole
Aptatargets SLMadridSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI